BOXED WARNING BOXED WARNING
Use: Labeled indications
- INDICATIONS & USAGE Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide Injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic…
Full indications and usage US FDA label
INDICATIONS & USAGE Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide Injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide Injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy.
The Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide Injection may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers.
Radiological Examination Metoclopramide Injection may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine.
Contraindications
CONTRAINDICATIONS Metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g. in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. Metoclopramide is contraindicated in patients with pheochromocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumor.
Such hypertensive crises may be controlled by phentolamine. Metoclopramide is contraindicated in patients with known sensitivity or intolerance to the drug. Metoclopramide should not be used in epileptics or patients receiving other drugs, which are likely to cause extrapyramidal reactions, since the frequency and severity of seizures or extrapyramidal reactions may be increased.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE & ADMINISTRATION For the Relief of Symptoms Associated with Diabetic Gastroparesis (Diabetic Gastric Stasis) If only the earliest manifestations of diabetic gastric stasis are present, oral administration of metoclopramide may be initiated. However, if severe symptoms are present, therapy should begin with Metoclopramide Injection (intramuscular or intravenous).
Doses of 10 mg may be administered slowly by the intravenous route over a 1 to 2 minute period. Administration of Metoclopramide Injection, USP up to 10 days may be required before symptoms subside, at which time oral administration of metoclopramide may be instituted. The physician should make a thorough assessment of the risks and benefits prior to prescribing further Metoclopramide treatment.
For the Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Intravenous infusions should be made slowly over a period of not less than 15 minutes, 30 minutes before beginning cancer chemotherapy and repeated every 2 hours for two doses, then every 3 hours for three doses. The initial two doses should be 2 mg/kg if highly emetogenic drugs such as cisplatin or dacarbazine are used alone or in combination.
For less emetogenic regimens, 1 mg/kg per dose may be adequate. For doses in excess of 10 mg, Metoclopramide Injection, USP should be diluted in 50 mL of a parenteral solution. The preferred parenteral solution is Sodium Chloride Injection (normal saline), which when combined with Metoclopramide Injection, USP can be stored frozen for up to 4 weeks.
Metoclopramide Injection, USP is degraded when admixed and frozen with Dextrose-5% in Water. Metoclopramide Injection, USP diluted in Sodium Chloride Injection, Dextrose-5% in Water, Dextrose-5% in 0.45% Sodium Chloride, Ringer's Injection or Lactated Ringer's Injection may be stored up to 48 hours (without freezing) after preparation if protected from light.
All dilutions may be stored unprotected from light under normal light conditions up to 24 hours after preparation. If acute dystonic reactions should occur, inject 50 mg Benadryl® (diphenhydramine hydrochloride) intramuscularly, and the symptoms usually will subside. For the Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection, USP should be given intramuscularly near the end of surgery.
The usual adult dose is 10 mg; however, doses of 20 mg may be used. To Facilitate Small Bowel Intubation If the tube has not passed the pylorus with conventional maneuvers in 10 minutes, a single dose (undiluted) may be administered slowly by the intravenous route over a 1 to 2 minute period. The recommended single dose is: Pediatric patients above 14 years of age and adults – 10 mg metoclopramide base.
Pediatric patients (6 to 14 years of age) – 2.5 to 5 mg metoclopramide base; (under 6 years of age) – 0.1 mg/kg metoclopramide base. To Aid in Radiological Examinations In patients where delayed gastric emptying interferes with radiological examination of the stomach and/or small intestine, a single dose may be administered slowly by intravenous route over a 1 to 2 minute period.
For dosage, see intubation above. Use in Patients with Renal or Hepatic Impairment Since metoclopramide is excreted principally through the kidneys, in those patients whose creatinine clearance is below 40 mL/min, therapy should be initiated at approximately one-half the recommended dosage. Depending upon clinical efficacy and safety considerations, the dosage may be increased or decreased as appropriate.
See OVERDOSAGE section for information regarding dialysis. Metoclopramide undergoes minimal hepatic metabolism, except for simple conjugation. Its safe use has been described in patients with advanced liver disease whose renal function was normal. NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dosing: Altered kidney function
Use in Patients with Renal or Hepatic Impairment Since metoclopramide is excreted principally through the kidneys, in those patients whose creatinine clearance is below 40 mL/min, therapy should be initiated at approximately one-half the recommended dosage.
See OVERDOSAGE section for information regarding dialysis.
Its safe use has been described in patients with advanced liver disease whose renal function was normal.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- ) solution for injection: 5 mg/mL (10 mg/2 mL, 10 mg/2 mL (5 mg/mL
- Solution for injection: 5 mg/mL
- Tablet: 10 mg
- Syrup: 5 mg/5 mL
- Film-coated tablet: 10 mg
- ) oral solution: 1 mg/mL (5 mg/5 mL
- ) solution f or injection: 5 mg/mL (10 mg/2 mL
- ) solution for injection : propulsive: 5 mg/mL (10 mg/2 mL
- )solution for injection: 5 mg/mL(10 mg/2 mL
Registered products in the Philippines
51 products registered with the Food and Drug Administration (FDA) Philippines list Metoclopramide as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Metoclopromide (as Hydrochloride) (1 product). Products registered under these spellings are included in the table and marked.
All registered products51
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AepramideMetoclopramide (as hydrochloride) | 5 mg/mL (10 mg/2 mL) Solution for Injection (IM/IV)Amber glass ampoule x 2 mL (Box of 10's) | Rx | Shandong Qidu PharmaceuticalChina | Dynasty Pharmaceuticals | DRP-15881 | Sep 25, 2029 | |
ArcimetMetoclopramide (as Hydrochloride) | 5 mg/ mL Solution for Injection (IM/IV)2 mL USP Type I clear glass ampoule in plastic tray (Box of 10's) | Rx | Farbe FirmaIndia | Vitalis Pharma Phil. Corp.Importer: AMB HK Enterprises Inc. | DRP-12163-01 | Jun 23, 2027 | |
ClomiteneMetoclopramide (as Hydrochloride) | 5 mg/mL Solution for Injection (I.M./I.V.)USP Type I Amber Glass Ampoule x 2 mL (Box of 50's) | Rx | L.B.S. Laboratory Limited PartnershipThailand | Phil. Pharmawealth, Inc. | DR-XY28309 | Feb 10, 2028 | |
CloprimedMetoclopramide (as hydrochloride) | 5 mg/mL (10 mg/2 mL) Solution for Injection (I.M./I.V.)Low Density Polyethylene Ampoule in laminated foil pouch x 5's (Box of 30's) | Rx | Euro-Med Laboratories Phil., Inc.Philippines | — | DR-XY 36421 | Aug 7, 2029 | |
DisurvanMetoclopramide (as hydrochloride) | 5 mg/5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-1569 | Feb 18, 2028 | |
GastrolexMetoclopramide (as hydrochloride) | 5 mg/5 mL SyrupAmber boston round glass bottle with aluminum pilfer- proof cap x 60 mL (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-15682 | Aug 22, 2029 | |
GastromideMetoclopramide hydrochloride | 5 mg/mL Solution for Injection (I.M./I.V.)USP Type I Amber Glass Ampoule x 2 mL (Box of 10's) | Rx | Gland Pharma LimitedIndia | Endure Medical, Inc. | DR-XY42981 | Jan 15, 2031 | |
5 mg/5 mL SyrupRound Amber Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Nutramedica Inc.Trader: D.B. Manix International, Inc. | DRP-11611 | Oct 28, 2031 | ||
LiothylMetoclopramide Hydrochloride | 10mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | YSP Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines),Inc. | DR-XY30184 | Oct 28, 2029 | |
LiothylMetoclopramide (as hydrochloride) | 5 mg/mL (10 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Amber Glass Ampoule x 2 mL (Box of 10's) | Rx | Y.S.P. Industries (M)Malaysia | Yung Shin (Philippines), Inc. | DRP-16387 | Feb 26, 2030 | |
LiothylMetoclopramide (as hydrochloride) | 5mg/mL (10mg/2mL) Solution for Injection (I.M./I.V. Infusion)Amber Glass Ampoule x 2 mL (Box of 10's) | Rx | Yung Shin Pharm. Ind. Co., Ltd. - Taichung Youth FactoryTaiwan | Yung Shin (Philippines), Inc. | DRP-7834 | Feb 19, 2031 | |
MeclopMetoclopramide (as hydrochloride) | 5 mg/mL Solution for Injection (IM/IV)Ampoule x 2 mL (Box of 1 plastic tray x 10’s) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | Aglobal Care, Inc. | DR-XY46009 | Sep 11, 2027 | |
MetadyMetoclopramide (as hydrochloride) | 10 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Huazhong Pharmaceuticals Co., Ltd.China | AMB HK Enterprises, Inc. | DRP-17580 | Feb 4, 2031 | |
MetoMetoclopramide (as Hydrochloride) | 10 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 100's | Rx | Centurion Remedies Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-5263 | Jul 20, 2029 | |
MetoMetoclopramide(as hydrochloride) | 5mg/mL(10mg/2mL)Solution for Injection(IM/Slow IV)USP Type III Amber Glass Ampoule x 2mL (10 ampoules in a plastic tray; Box of 10's); USP Type III Amber Glass Ampoule x 2mL (10 ampoules in a plastic tray; Box of 100's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Health Saver Pharma Inc. | DRP-2030 | Jul 9, 2027 | |
MetocircMetoclopramide Hydrochloride | 5 mg / mL Solution for Injection (IM/IV)USP Type I Amber glass ampoule x 2 mL (Box of 5’s) | Rx | Scott-Edil Pharmacia Ltd.India | PharmaCircle Enterprise CorporationImporter: Pharmakon Biotec Inc. | DRP-14225-01 | Dec 27, 2027 | |
MetoclonMetoclopramide Hydrochloride | 5 mg/mL (10 mg/2 mL) Solution for Injection (IM/IV)Clear Glass Ampule (USP Type-1) x 2mL with PVC Tray (Box of 20's) | Rx | Indus Pharma (Pvt.) Ltd.Pakistan | Importer: One Dexcel Pharma Inc. | DRP-11266 | Feb 21, 2027 | |
MetoclosaphMetoclopramide Hydrochloride | 1 mg/mL (5 mg/5 mL) Oral Solution60 mL Round Amber PET bottle with white ROPP aluminum cap (Box of 1's) | Rx | Enicar Pharmaceuticals Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13737 | Apr 3, 2028 | |
MetoclosilMetoclopramide | 5mg/mL (10 mg/2 mL) Solution for Injection2mL BP Type II Clear and Colorless Glass Ampoule (Box of 10's in Plastic Tray) Box of 10's | Rx | Anhui Chengshi Pharmaceutical Co., Ltd.China | 2 World Traders Inc.Trader: Ningbo Tisun Medic Biochemic Co., Ltd. | DR-XY45477 | Jun 30, 2036 | |
MetocolMetoclopramide (as hydrochloride) | 5 mg/mL (10 mg/2 mL) Solution for Injection (I.M./I.V.)2 mL USP Type I amber glass ampoule (Box of 10's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Aglobal Care, Inc. | DRP-13300 | Jan 19, 2028 | |
MetodenMetoclopramide (as Hydrochloride) | 5 mg / mL Solution for Injection (IM/IV)2 mL USP Type I clear glass ampoule in plastic tray (Box of 10's) | Rx | Farbe Firma Pvt. LtdIndia | Cyden Medicale Trading Inc.Importer: AMB HK Enteprises Inc. | DRP-12163-03 | Jun 23, 2027 | |
MetofarMetoclopramide Hydrochloride | 5 mg / mL Solution for Injection (IM/IV)USP Type I Amber glass ampoule x 2 mL ( Box of 5’s ) | Rx | Scott-Edil Pharmacia Ltd.India | Pharmakon Biotec Inc. | DRP-14225 | Dec 27, 2027 | |
MetofarMetoclopramide Hydrochloride | 5 mg/mL Solution for Injection (IM/IV)USP Type 1 Amber glass ampoule x 2 mL (Box of 5’s) | Rx | SCOTT-EDIL PHARMACIA LTD.India | PHARMAKON BIOTEC INC. | DR-XY41519 | Dec 27, 2027 | |
MetogardMetoclopramide (as Hydrochloride) | 10 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., IncPhilippines | — | DRP-3484 | Jan 16, 2030 | |
MetopraMetoclopramide (as Hydrochloride) | 5 mg/5 mL SyrupBoston Round Amber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc. | DR-XY39782 | Jul 18, 2031 | |
MetosanMetoclopramide (as hydrochloride) | 5 mg/mL (10 mg/2 mL) Solution for InjectionUSP Type I Amber Glass Ampoule x 2 mL in clear plastic tray (Box of 5's) | Rx | Mackur Laboratories LimitedIndia | SRS Life Sciences, Inc. | DRP-2580 | Nov 2, 2028 | |
MetoskyMetoclopramide (as hydrochloride) | 5 mg/mL (10 mg/2 mL) Solution for Injection (IM/IV)USP Type I amber glass ampoule x 2 mL in blister tray. (Box of 5's) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-14766 | Jan 2, 2029 | |
MetoxariMetoclopramide (as hydrochloride) | 5 mg/mL (10 mg/ 2 mL) Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 2 mL x 10 Ampoules (Box of 10's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Ambica International Corporation | DRP-15394 | Jul 2, 2029 | |
MetrexMetoclopramide hydrochloride | 5 mg/mL (10 mg/2 mL) Solution for Injection (I.M./I.V.)2 mL USP Type I amber glass ampoule Box of 10 ampoules | Rx | Grand Pharmaceutical (China) Co., Ltd.China | Aarex Pharma DistributorsTrader: Advacare International Limited | DR-XY45834 | Mar 27, 2027 | |
MetvexMetoclopramide Hydrochloride | 10mg/2ml (5mg/ml) Solution for Injection (I.M./Slow I.V.)2ml Type II Amber Glass Ampoule Box of 10's | Rx | SHANDONG XIERKANGTAI PHARMACEUTICAL CO. LTD.China | Sannovex Pharmaceutical Distributor | DRP-2509 | Jun 25, 2028 | |
MotillexMetoclopramide (as Hydrochloride) | 10mg TabletAlu/Red PVC Blister Pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | — | DRP-7206 | Aug 3, 2028 | |
MotillexMetoclopramide (as Hydrochloride) | 5 mg/5 mL SyrupAmber glass bottle x 60 mL (Box of 1's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-373 | Jul 8, 2027 | |
MyclosilMetoclopramide Hydrochloride | 10 mg TabletAlu-Clear PVC Blister Pack x 20's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-2258 | Jun 15, 2030 | |
MyclosilMetoclopramide (as hydrochloride) | 5 mg/5 mL Syrup (Orange Flavor)Amber Glass Bottle x 60 mL (Box of 1's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-1865 | Jan 28, 2030 | |
NausilMetoclopramide (as hydrochloride) | 5 mg/mL Solution for Injection (IM/IV)USP Type I Clear and colorless glass ampoule x 2 mL (Box of 50's) | Rx | T.P. Drug Laboratories (1969) Co., Ltd.Thailand | Lordla Pharma Sales | DRP-710 | Apr 28, 2029 | |
NoneMetoclopramide (as Hydrochloride) | 10 mg TabletAlu/Red PVC Blister Pack x 20's (Box of 100"s) | Rx | Drugmaker’s Laboratories Inc.Philippines | TGP Pharma Inc. | DRP-7206-01 | Aug 3, 2028 | |
NoneMetoclopramide (as hydrochloride) | 5mg/5mL SyrupAmber glass bottle x 60mL Box of 1's | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-373-01 | Jul 8, 2027 | |
PlasilMetoclopramide (as Hydrochloride) | 10 mg TabletAlu Foil/Cello/PE x 10's (Box of 100's) | Rx | Sanofi S.R.L.Italy | Importer: sanofi-aventis Philippines, Inc. | DRP-6568 | Mar 30, 2031 | |
PlasilMetoclopramide (as hydrochloride) | 5 mg/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 2 mL (Box of 5's) | Rx | Sanofi S.R.L.Italy | Sanofi-Aventis Philippines, Inc. | DRP-5151 | Nov 24, 2031 | |
PlazimideMetoclopramide Hydrochloride | 5 mg/mL (10 mg/2 mL) Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule in 2 mL (net content) (Box of 10's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DR-XY45206 | Mar 17, 2031 | |
PramideMetoclopramide Hydrochloride | 5 mg/mL (10 mg/2 mL) Solution for Injection (IM/IV) : Propulsive2 mL USP Type I clear glass ampoule in plastic tray (Box of 10's) | Rx | Guizhou Tiandi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc | DRP-17035 | Sep 12, 2030 | |
PramideMetoclopramide (As Hydrochloride) | 5mg/mL Solution For Injection (I.M./I.V.)2 mL USP Type I clear glass ampoule in plastic tray (Box of 10's) | Rx | Farbe FirmaIndia | AMB HK Enterprises Inc. | DRP-12163 | Jun 23, 2027 | |
RafromideMetoclopramide (as hydrochloride) | 10 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Foramen Products Corporation | DR-XY28208 | Jan 15, 2028 | |
RafromideMetoclopramide (as hydrochloride) | 10 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Foramen Products Corporation | DRP-13274 | Jan 15, 2028 | |
RapramideMetoclopramide Hydrochloride | 5 mg/mL (10 mg/2mL) Solution for Injection (I.M./I.V.)2 mL Amber glass ampoule in PVC tray (Box of 10’s) | Rx | Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China | Raquel Abbas Pharma Inc. | DRP-19081 | Oct 26, 2031 | |
RegastinMetoclopramide (as hydrochloride) | 5 mg/mL (10 mg / 2 mL) Solution f or Injection (IM/IV)Type-I Amber Glass Ampoule x 2 mL in Plastic Tray (Box of 1's, 5's, 10's, 50's, and 100's) | Rx | Cotec Healthcare Pvt. Ltd.India | Despina Pharma Inc. | DRP-18427 | Jul 8, 2031 | |
SaphclomideMetoclopramide | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-13832 | Apr 7, 2031 | |
Saphclomide-GE10Metoclopramide (as hydrochloride) | 10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-18890 | Sep 24, 2031 | |
SaphmetocMetoclopramide hydrochloride | 5 mg/mL (10 mg/2 mL) Solution for Injection (I.M./I.V.)2 mL (net content) USP Type I amber glass ampoule in plastic tray (box of 10 ampoules) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-16402 | Mar 3, 2030 | |
ZaeclopMetoclopramide Hydrochloride | 5 mg / mL Solution for Injection (IM/IV)USP Type I Amber glass ampoule x 2 mL (Box of 5’s) | Rx | Scott-Edil Pharmacia Ltd.India | Rifemedica CorporationImporter: Pharmakon Biotec Inc. | DRP-14225-02 | Dec 27, 2027 | |
(no brand name)Metoclopramide (as hydrochloride) | 5 mg/mL Solution for Injection (IM/IV)Amber glass ampoules x 2 mL of 10 ampoules x 2 mL in carton tray) | Rx | Merit Organics LtdIndia | Khriz Pharma Trading Inc.Trader: Lob International | DR-XY49466 | Aug 6, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
ADMIXTURES COMPATIBILITIES Metoclopramide Injection, USP is compatible for mixing and injection with the following dosage forms to the extent indicated below: Physically and Chemically Compatible up to 48 Hours Cimetidine Hydrochloride (SK&F), Mannitol, USP (Abbott), Potassium Acetate, USP (Invenex), Potassium Phosphate, USP (Invenex). Physically Compatible up to 48 Hours Ascorbic Acid, USP (Abbott), Benztropine Mesylate, USP (MS&D), Cytarabine, USP (Upjohn), Dexamethasone Sodium Phosphate, USP (ESI, MS&D), Diphenhydramine Hydrochloride, USP (Parke-Davis), Doxorubicin Hydrochloride, USP (Adria), Heparin Sodium, USP (ESI), Hydrocortisone Sodium Phosphate (MS&D), Lidocaine Hydrochloride, USP (ESI), Multi-Vitamin Injection (must be refrigerated - USV), Vitamin B Complex with Ascorbic Acid (Roche).
Physically Compatible up to 24 Hours (Do not use if precipitation occurs) Clindamycin Phosphate, USP (Upjohn), Cyclophosphamide, USP (Mead-Johnson), Insulin, USP (Lilly). Conditionally Compatible (Use within one hour after mixing or may be infused directly into the same running IV line) Ampicillin Sodium, USP (Bristol), Cisplatin (Bristol), Erythromycin Lactobionate, USP (Abbott), Methotrexate Sodium, USP (Lederle), Penicillin G Potassium, USP (Squibb), Tetracycline Hydrochloride, USP (Lederle).
Incompatible (Do Not Mix) Cephalothin Sodium, USP (Lilly), Chloramphenicol Sodium, USP (Parke-Davis), Sodium Bicarbonate, USP (Abbott)
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS Neuroleptic Malignant Syndrome (NMS) There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).
The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g. pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS).
Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever and primary central nervous system (CNS) pathology. The management of NMS should include 1) immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available.
Bromocriptine and dantrolene sodium have been used in treatment of NMS, but their effectiveness have not been established (see ADVERSE REACTIONS). Extrapyramidal Symptoms (EPS) Acute Dystonic Reactions Acute dystonic reactions occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide.
These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at the higher doses used in prophylaxis of vomiting due to cancer chemotherapy. These symptoms may include involuntary movements of limbs and facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, or dystonic reactions resembling tetanus.
Rarely, dystonic reactions may present as stridor and dyspnea, possibly due to laryngospasm. If these symptoms should occur, inject 50 mg Benadryl® (diphenhydramine hydrochloride) intramuscularly, and they usually will subside. Cogentin® (benztropine mesylate), 1 to 2 mg intramuscularly, may also be used to reverse these reactions.
Tardive Dyskinesia (see BOXED WARNING) Treatment with Metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.
An analysis of utilization patterns showed that about 20% of patients who used Metoclopramide took it for longer than 12 weeks. Treatment with Metoclopramide for longer than the recommended 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD. Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop Metoclopramide-induced TD.
Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose. Metoclopramide should be discontinued in patients who develop signs or symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after Metoclopramide is withdrawn.
Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Therefore, Metoclopramide should not be used for the symptomatic control of TD. Parkinsonian-like Symptoms Parkinsonian-like symptoms, including bradykinesia, tremor, cogwheel rigidity, or mask-like facies, have occurred more commonly within the first 6 months after beginning treatment with Metoclopramide, but occasionally after longer periods.
These symptoms generally subside within 2 to 3 months following discontinuation of Metoclopramide. Patients with preexisting Parkinson's disease should be given Metoclopramide cautiously, if at all, since such patients may experience exacerbation of Parkinsonian symptoms when taking Metoclopramide. Depression Mental depression has occurred in patients with and without prior history of depression.
Symptoms have ranged from mild to severe and have included suicidal ideation and suicide. Metoclopramide should be given to patients with a prior history of depression only if the expected benefits outweigh the potential risks.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS In general, the incidence of adverse reactions correlates with the dose and duration of metoclopramide administration. The following reactions have been reported, although in most instances, data do not permit an estimate of frequency: CNS Effects Restlessness, drowsiness, fatigue and lassitude may occur in patients receiving the recommended prescribed dosage of Metoclopramide Injection.
Insomnia, headache, confusion, dizziness or mental depression with suicidal ideation also may occur (see WARNINGS). In cancer chemotherapy patients being treated with 1 to 2 mg/kg per dose, incidence of drowsiness is about 70%. There are isolated reports of convulsive seizures without clear-cut relationship to metoclopramide.
Rarely, hallucinations have been reported. Extrapyramidal Reactions (EPS) Acute dystonic reactions, the most common type of EPS associated with metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of metoclopramide per day. In cancer, chemotherapy patients receiving 1 to 2 mg/kg per dose, the incidence is 2% in patients over the ages of 30 to 35, and 25% or higher in pediatric patients and adult patients less than 30 years of age who have not had prophylactic administration of diphenhydramine.
Symptoms include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions), and rarely, stridor and dyspnea possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine (see WARNINGS). Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, mask-like facies (see WARNINGS).
Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth, or jaw and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance (see WARNINGS). Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, foot tapping.
These symptoms may disappear spontaneously or respond to a reduction in dosage. Neuroleptic Malignant Syndrome Rare occurrences of Neuroleptic malignant syndrome (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of hyperthermia, muscular rigidity, altered consciousness, and autonomic instability (see WARNINGS).
Endocrine Disturbances Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia (see PRECAUTIONS). Fluid retention secondary to transient elevation of aldosterone (see CLINICAL PHARMACOLOGY). Cardiovascular Hypotension, hypertension, supraventricular tachycardia, bradycardia, fluid retention, acute congestive heart failure and possible atrioventricular (AVA) block (see CONTRAINDICATIONS and PRECAUTIONS).
Gastrointestinal Nausea and bowel disturbances, primary diarrhea. Hepatic Rarely, cases of hepatotoxicity, characterized by such findings as jaundice and altered liver function tests, when metoclopramide was administered with other drugs with known hepatotoxic potential. Renal Urinary frequency and incontinence. Hematologic A few cases of neutropenia, leucopenia, or agranulocytosis, generally without clear-cut relationship to metoclopramide.
Methemoglobinemia in adults and especially with overdosage in neonates (see OVERDOSAGE). Sulfhemoglobinemia in adults. Allergic Reactions A few cases of rash, urticaria, or bronchospasm, especially in patients with a history of asthma. Rarely, angioneurotic edema, including glossal or laryngeal edema. Miscellaneous Visual disturbances, Porphyria.
Transient flushing of the face and upper body, without alterations in vital signs, following high doses intravenously.
Pharmacokinetics
The average elimination half-life in individuals with normal renal function is 5 to 6 hr.
Of the 85% eliminated in the urine, about half is present as free or conjugated metoclopramide.
In a study with patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, non-renal clearance, and increase in elimination half-life.
After the tenth dose, the mean time to reach peak concentrations (2.2 hr), half-life (4.1 hr), clearance (0.67 L/h/kg), and volume of distribution (4.4 L/kg) of metoclopramide were similar to those observed after the first dose.
In the youngest patient (age, 3.5 weeks), metoclopramide half-life after the first and the tenth dose (23.1 and 10.3 hr, respectively) was significantly longer compared to other infants due to reduced clearance.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not dependent on intact vagal innervation, but it can be abolished by anticholinergic drugs.
Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter.
It has little, if any, effect on the motility of the colon or gallbladder. In patients with gastroesophageal reflux and low LESP (lower esophageal sphincter pressure), single oral doses of metoclopramide produce dose-related increases in LESP. Effects begin at about 5 mg and increase through 20 mg (the largest dose tested).
The increase in LESP from a 5 mg dose lasts about 45 minutes and that of 20 mg lasts between 2 and 3 hours. Increased rate of stomach emptying has been observed with single oral doses of 10 mg. The antiemetic properties of metoclopramide appear to be a result of its antagonism of central and peripheral dopamine receptors.
Dopamine produces nausea and vomiting by stimulation of the medullary chemoreceptor trigger zone (CTZ), and metoclopramide blocks stimulation of the CTZ by agents like l-dopa or apomorphine which are known to increase dopamine levels or to possess dopamine-like effects. Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine.
Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions, although these are comparatively rare (see WARNINGS). Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.
The onset of pharmacological action of metoclopramide is 1 to 3 minutes following an intravenous dose, 10 to 15 minutes following intramuscular administration, and 30 to 60 minutes following an oral dose; pharmacological effects persist for 1 to 2 hours. Pharmacokinetics Metoclopramide is rapidly and well absorbed. Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects.
Peak plasma concentrations occur at about 1 to 2 hr after a single oral dose. Similar time to peak is observed after individual doses at steady state. In a single dose study of 12 subjects, the area under the drug concentration-time curve increases linearly with doses from 20 to 100 mg. Peak concentrations increase linearly with dose; time to peak concentrations remains the same; whole body clearance is unchanged; and the elimination rate remains the same.
The average elimination half-life in individuals with normal renal function is 5 to 6 hr. Linear kinetic processes adequately describe the absorption and elimination of metoclopramide. Approximately 85% of the radioactivity of an orally administered dose appears in the urine within 72 hrs. Of the 85% eliminated in the urine, about half is present as free or conjugated metoclopramide.
The drug is not extensively bound to plasma proteins (about 30%). The whole body volume of distribution is high (about 3.5 L/kg) which suggests extensive distribution of drug to the tissues. Renal impairment affects the clearance of metoclopramide. In a study with patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, non-renal clearance, and increase in elimination half-life.
The kinetics of metoclopramide in the presence of renal impairment remained linear however. The reduction in clearance as a result of renal impairment suggests that adjustment downward of maintenance dosage should be done to avoid drug accumulation. Adult Pharmacokinetic Data In pediatric patients, the pharmacodynamics of metoclopramide following oral and intravenous administration are highly variable and a concentration-effect relationship has not been established.
There are insufficient reliable data to conclude whether the pharmacokinetics of metoclopramide in adults and the pediatric population are similar. Although there are insufficient data to support the efficacy of metoclopramide in pediatric patients with symptomatic gastroesophageal reflux (GER) or cancer chemotherapy-related nausea and vomiting, its pharmacokinetics have been studied in these patient populations.
In an open-label study, six pediatric patients (age range, 3.5 weeks to 5.4 months) with GER received a metoclopramide 0.15 mg/kg oral solution every 6 hours for 10 doses. The mean peak plasma concentration of metoclopramide after the tenth dose was 2-fold (56.8 mcg/L) higher compared to that observed after the first dose (29 mcg/L) indicating drug accumulation with repeated dosing.
After the tenth dose, the mean time to reach peak concentrations (2.2 hr), half-life (4.1 hr), clearance (0.67 L/h/kg), and volume of distribution (4.4 L/kg) of metoclopramide were similar to those observed after the first dose. In the youngest patient (age, 3.5 weeks), metoclopramide half-life after the first and the tenth dose (23.1 and 10.3 hr, respectively) was significantly longer compared to other infants due to reduced clearance.
This may be attributed to immature hepatic and renal systems at birth. Single intravenous doses of metoclopramide 0.22 to 0.46 mg/kg (mean, 0.35 mg/kg) were administered over 5 minutes to 9 pediatric cancer patients receiving chemotherapy (mean age 11.7 years; range 7 to 14 yr) for prophylaxis of cytotoxic-induced vomiting.
The metoclopramide plasma concentrations extrapolated to time zero ranged from 65 to 395 mcg/L (mean, 152 mcg/L). The mean elimination half-life, clearance, and volume of distribution of metoclopramide were 4.4 hr (range, 1.7 to 8.3 hr), 0.56 L/h/kg (range, 0.12 to 1.20 L/h/kg), and 3.0 L/kg (range, 1.0 to 4.8 L/kg), respectively.
In another study, nine pediatric cancer patients (age range 1 to 9 yr) received 4 to 5 intravenous infusions (over 30 minutes) of metoclopramide at a dose of 2 mg/kg to control emesis. After the last dose, the peak serum concentrations of metoclopramide ranged from 1060 to 5680 mcg/L. The mean elimination half-life, clearance, and volume of distribution of metoclopramide were 4.5 hr (range, 2.0 to 12.5 hr), 0.37 L/h/kg (range, 0.10 to 1.24 L/h/kg), and 1.93 L/kg (range, 0.95 to 5.50 L/kg), respectively.
Pediatric Pharmacokinetic Studies a SEM not available 1. Bateman, DN, et al. Br J Clin Pharmac 15:557-559, 1983 2. Ford, C. Clin Pharmac Ther 43 :196, 1988. CLINICAL PHARMA 1 CLINICAL PHARMA 2
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Metoclopramide 5 mg/5 mL, 60 mL Syrup | ₱19.50–₱25.70Reference ₱19.50 | per unit | DPRI procurement range |
| Metoclopramide 5 mg/mL, 2 mL Ampule | ₱3.08–₱15.00Reference ₱3.97 | per ampule | DPRI procurement range |
| Metoclopramide 10 mg Tablet | ₱0.79–₱4.50Reference ₱1.73 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Metoclopramide |
| PNF listing | Oral: 10 mg tablet (as hydrochloride) |
| PNF listing | Oral: 5 mg/5 mL syrup, 60 mL (as base and as hydrochloride) |
| PNF listing | Inj.: 5 mg/mL, 2 mL ampul (IM, IV) (as base and as hydrochloride) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. METOCLOPRAMIDE · HF Acquisition Co LLC, DBA HealthFirst [US FDA-approved label, version 3, December 10, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .